Marcellus Petrus Maria Stokkel

Marcellus Petrus Maria Stokkel

Auto-generated profile, based on publicly available information

Marcellus Petrus Maria Stokkel

Department of Nuclear Medicine, Netherlands Cancer Institute – Antoni van Leeuwenhoek hospital, Amsterdam, Kingdom of the Netherlands

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2010 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MSMarcel P. M. Stokkel
Marcel P. M. Stokkel
DHDaria Handkiewicz-Junak
Daria Handkiewicz-Junak
MLMichael Lassmann
Michael Lassmann
MDMarkus Dietlein
Markus Dietlein
MLMarkus Luster
Markus Luster

29 August 2018 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
DHDaphne Merel Valerie Huizing
Daphne Merel Valerie Huizing
BVBerlinda Jantina De Wit – Van Der Veen
Berlinda Jantina De Wit – Van Der Veen
MVMarcel Verheij
Marcel Verheij
MSMarcellus Petrus Maria Stokkel
Marcellus Petrus Maria Stokkel
The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue irradiation. Dosimetry could help to increase therapy response and decrease toxicity after SRT by individual treatment planning. Peptide receptor radionuclide therapy (PRRT) is an accepted SRT treatment option for irresectable and metastatic neuroendocrine tumours (NET). However, dosimetry in PRRT is not routinely performed, mainly due to the lack of evidence in literature and clinical implementation difficulties. The goal of this review is to provide insight in dosimetry methods and requirements and to present an overview of clinical aspects of dosimetry in PRRT for NET. A PubMed query including the search criteria dosimetry, radiation dose, peptide receptor radionuclide therapy, and radionuclide therapy was performed. Articles were selected based on title and abstract, and description of dosimetric approach. A total of 288 original articles were included. The most important dosimetry methods, their main advantages and limitations, and implications in the clinical setting are discussed. An overview of dosimetry in clinical studies regarding PRRT treatment for NET is provided. Clinical dosimetry in PRRT is feasible and can result in improved treatment outcomes. Current clinical dosimetry studies focus on safety and apply non-voxel-based dosimetry methods. Personalised treatment using sophisticated dosimetry methods to assess tumour and normal tissue uptake in clinical trials is the next step towards routine dosimetry in PRRT for NET.

1 April 2017 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
MLMelanie A. Lindenberg
Melanie A. Lindenberg
AMAnna Miquel-Cases
Anna Miquel-Cases
VRValesca P. Retel
Valesca P. Retel
GSGabe S. Sonke
Gabe S. Sonke
JWJelle Wesseling
Jelle Wesseling
WHWim van Harten
Wim van Harten

5 June 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TGTHYROPET study group
THYROPET study group
JKJakob W Kist
Jakob W Kist
BKBart De Keizer
Bart De Keizer
MSMarcel Pm Stokkel
Marcel Pm Stokkel
OHOtto S Hoekstra
Otto S Hoekstra
WVWouter V Vogel
Wouter V Vogel
After initial treatment of differentiated thyroid carcinoma (DTC) patients are followed with thyroglobulin (Tg) measurements to detect recurrences. In case of elevated levels of Tg and negative neck ultrasonography, patients are treated 'blindly' with Iodine-131 (131I). However, in up to 50% of patients, the post-therapy scan reveals no 131I-targeting of tumor lesions. Such patients derive no benefit from the blind therapy but are exposed to its toxicity. Alternatively, iodine-124 (124I) Positron Emission Tomography/Computed Tomography (PET/CT) has become available to visualize DTC lesions and without toxicity. In addition to this, 18F-fluorodeoxyglucose (18F-FDG) PET/CT detects the recurrent DTC phenotype, which lost the capacity to accumulate iodine. Taken together, the combination of 124I and 18F-FDG PET/CT has potential to stratify patients for treatment with 131I.

1 January 2013 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
MSMarcel P.M. Stokkel
Marcel P.M. Stokkel
BVBerlinda Jantina De Wit – Van Der Veen
Berlinda Jantina De Wit – Van Der Veen
ABAnnelies Boekhout
Annelies Boekhout
Introduction Cardiotoxicity related to trastuzumab anticancer treatment poses a diagnostic challenge at early stages. The aim of the present pilot study was to assess the value of iodine-123-metaiodobenzylguanidine (I-123-MIBG) scintigraphy in breast cancer patients treated with trastuzumab who showed a decrease in their cardiac function. Materials and methods I-123-MIBG scintigraphy was performed in nine patients with decreased or significantly decreasing left ventricular ejection fraction (LVEF) during trastuzumab therapy. On the basis of planar images, 4 h heart-to-mediastinum (HMR) ratio and washout percentages (WR) were calculated. Results I-123-MIBG scintigraphy revealed abnormal 4 h HMR and increased WR in three patients. LVEF recovery was observed in none of these patients during 3, 6, and 13 months of follow-up. In two of five patients with normal 4 h HMR the washout rates were also normal, whereas in three patients slightly increased washout rates were found. All five patients demonstrated a recovery of their LVEF value during follow-up. One patient with a normal 4 h HMR and normal WR initially showed a significant decrease in LVEF, which decreased further during follow-up. However, the LVEF value remained at 53%, which was within normal limits, after trastuzumab administration. Conclusion In this pilot study we have explored the role of I-123-MIBG scintigraphy in the assessment of trastuzumab-related cardiotoxicity and suggest that, in patients with a persistently decreasing LVEF, I-123-MIBG scintigraphy might indicate whether recovery will occur and, consequently, whether retreatment may be initiated.

24 October 2019 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
DHDaan Hellingman
Daan Hellingman
MDMaarten Lucas Donswijk
Maarten Lucas Donswijk
GWGonneke A. O. Winter-Warnars
Gonneke A. O. Winter-Warnars
PKPetra de Koekkoek-Doll
Petra de Koekkoek-Doll
MPMarilyn Pinas
Marilyn Pinas
MSMarcel P. M. Stokkel
Marcel P. M. Stokkel
Background: Selective removal of initially tumor-positive axillary lymph nodes in breast cancer patients who underwent neoadjuvant systemic treatment (NST) improves the accuracy of nodal staging and provides the opportunity for more tailored axillary treatment. This study evaluated whether radioguided occult lesion localization (ROLL) of clip-marked lymph nodes is feasible in clinical practice. Methods: Prior to NST, a clip marker was placed inside a proven tumor-positive lymph node in all breast cancer patients (cTis-4N1-3 M0). After NST, technetium-99m-labeled macroaggregated albumin was injected in the clip-marked lymph nodes. The next day, these ROLL-marked nodes were selectively removed at surgery to evaluate the pathological response of the axilla. Results: Thirty-seven patients (38 axillae) underwent clip insertion. After NST, the clip was visible by ultrasound in 36 procedures (95%). In the other two patients, the ROLL-node injection was performed in a sonographically suspicious unclipped node (1), and near the clip under computed tomography guidance (1). Initial surgery successfully identified the ROLL-marked node with clip in 33 procedures (87%). Removed specimens in the other five procedures contained only the sonographically suspicious tumor-positive unclipped node (1), a node with signs of complete response but no clip (2), a clip without node (1), and tissue without node nor clip, and a second successful ROLL-node procedure was performed (1). Overall, 10 ROLL-marked nodes had no residual disease. Conclusions: This study demonstrates that the ROLL procedure to identify clip-marked lymph nodes is feasible. This facilitates selective removal at surgery and may tailor axillary treatment in patients treated with NST.